What is it about?
Despite their high risk for liver steatosis and fibrosis, patients with type 2 diabetes do not undergo routine screening for liver disease, with only 33% completing all the necessary tests for the initial screening.
Featured Image
Read the Original
This page is a summary of: Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: Are We Doing Enough?, Diabetes Spectrum, September 2025, American Diabetes Association,
DOI: 10.2337/ds25-0028.
You can read the full text:
Contributors
The following have contributed to this page
